Apr 09, 2025
TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells
Mar 21, 2025
TCBP Announces Transition from Nasdaq to OTC Markets
Mar 05, 2025
TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
Feb 20, 2025
TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
Feb 05, 2025
TCBP to Implement ADS Ratio Change
Dec 30, 2024
TCBP Issues 25% Stock Dividend
Dec 20, 2024
TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients
Dec 18, 2024
TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend
Dec 11, 2024
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
Dec 04, 2024
TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial
Nov 12, 2024
TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
Oct 30, 2024
TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
Oct 25, 2024
TCBP Responds to False Social Media Claim
Oct 22, 2024
TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
Oct 03, 2024
TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
Sep 25, 2024
TCBP Announces Site Opening of Guys and St. Thomas Hospital
Sep 12, 2024
TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial
Sep 06, 2024
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
Sep 05, 2024
TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Sep 03, 2024
TCBP Announces Dosing of 5 New Patients in ACHIEVE